Inhibition of neutrophil-mediated production of reactive oxygen species (ROS) by endothelial cells is not impaired in anti-neutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitis patients.
Leucocyte transendothelial migration is strictly regulated to prevent undesired inflammation and collateral damage of endothelial cells by activated neutrophils/monocytes. We hypothesized that in anti-neutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitis (AAV) patients' dysregulation of this process might underlie vascular inflammation. Peripheral blood mononuclear cells (PBMC) and neutrophils from AAV patients (n = 12) and healthy controls (HC, n = 12) were isolated. The influence of human umbilical vein endothelial cells (HUVEC) on neutrophil/monocytes function was tested by N-formyl-methionyl-leucyl-phenyl-alanine (fMLP)- and phorbol 12-myristate 13-acetate (PMA)-mediated ROS production, degranulation and interleukin (IL)-8 production. In addition, the ability of lipopolysaccharide (LPS)-stimulated PBMC to produce tumour necrosis factor (TNF)-alpha in the presence or absence of HUVEC was tested. HUVEC inhibited ROS production dose-dependently by fMLP-stimulated neutrophils but did not influence degranulation. No differences between neutrophils from HC and AAV were found. However, in only one active patient was degranulation inhibited significantly by HUVEC only before cyclophosphamide treatment, but not 6 weeks later. Co-cultures of HUVEC with LPS-stimulated neutrophils/monocytes increased IL-8 production while TNF-alpha production was inhibited significantly. There was no apparent difference between AAV patients and HC in this respect. Our findings demonstrate that HUVEC are able to inhibit ROS and modulate cytokine production upon stimulation of neutrophils or monocytes. Our data do not support the hypothesis that endothelial cells inhibit ROS production of neutrophils from AAV patients inadequately. Impaired neutrophil degranulation may exist in active patients, but this finding needs to be confirmed.
Al Laham
F
F
Vth Medical Department, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany.
Kälsch
A-I
AI
Heinrich
L
L
Birck
R
R
Kallenberg
C G M
CG
Heeringa
P
P
Yard
B
B
D000243:Adenosine Deaminase / Q000494:pharmacology; D019830:Adenosine-5'-(N-ethylcarboxamide) / Q000494:pharmacology; D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000378:metabolism*; D002450:Cell Communication / Q000187:drug effects / Q000276:immunology; D015550:Cell Degranulation / Q000187:drug effects; D002478:Cells, Cultured; D018920:Coculture Techniques; D042783:Endothelial Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D016209:Interleukin-8 / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D009195:Peroxidase / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism*; D016897:Respiratory Burst / Q000187:drug effects; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D016209:Interleukin-8; D008070:Lipopolysaccharides; D017382:Reactive Oxygen Species; D014409:Tumor Necrosis Factor-alpha; D019830:Adenosine-5'-(N-ethylcarboxamide); D009240:N-Formylmethionine Leucyl-Phenylalanine; D009195:Peroxidase; D000243:Adenosine Deaminase; D013755:Tetradecanoylphorbol Acetate
Am J Physiol Cell Physiol. 2004 Aug;287(2):C260-2
15238358
Int Immunopharmacol. 2006 Mar;6(3):396-407
16428075
Biochem Pharmacol. 2005 Mar 15;69(6):883-9
15748700
J Am Soc Nephrol. 2002 Dec;13(12):2840-9
12444202
Am J Respir Cell Mol Biol. 2008 Jul;39(1):53-60
18276796
Am J Physiol Heart Circ Physiol. 2006 Jan;290(1):H365-72
16155097
J Exp Med. 2005 Apr 4;201(7):1113-23
15809354
J Biolumin Chemilumin. 1997 May-Jun;12(3):149-53
9427114
Pediatr Res. 2009 Apr;65(4):425-9
19127214
Science. 2006 Dec 15;314(5806):1792-5
17170310
Circ Res. 2006 Nov 10;99(10):1100-8
17038639
Annu Rev Pathol. 2009;4:71-95
18754744
Am J Physiol. 1999 Dec;277(6):G1222-30
10600820
Neurochem Res. 2001 Sep;26(8-9):959-69
11699948
Trends Cardiovasc Med. 2008 Apr;18(3):103-7
18436149
Br J Pharmacol. 2000 Mar;129(5):921-6
10696091
Adv Nephrol Necker Hosp. 1999;29:1-15
10561734
FASEB J. 2009 Feb;23(2):473-82
18838482
Curr Rheumatol Rep. 2004 Jun;6(3):184-94
15134597
Vet Immunol Immunopathol. 2008 Jan 15;121(1-2):91-100
17913243
Br J Pharmacol. 2007 Jul;151(5):628-37
17471175
Proc Natl Acad Sci U S A. 1990 Jun;87(11):4115-9
2161532
Arthritis Rheum. 2006 May;54(5):1619-28
16646023
J Am Soc Nephrol. 2002 Sep;13(9):2232-8
12191967
J Am Soc Nephrol. 2005 Jul;16(7):2216-24
15901769
J Immunol. 1985 Aug;135(2):1366-71
2989364
Kidney Int. 1999 Mar;55(3):852-63
10027922
Kidney Int. 2007 Oct;72(7):853-64
17667990
Shock. 2007 Jan;27(1):25-31
17172976
J Mol Cell Cardiol. 2004 Jan;36(1):101-10
14734052
J Appl Physiol (1985). 1996 Sep;81(3):1213-22
8889756
Am J Pathol. 2001 Feb;158(2):581-92
11159195
Nat Rev Mol Cell Biol. 2003 Apr;4(4):285-94
12671651
Lancet. 2003 Jan 18;361(9353):206-10
12547543